SEC Form SC 13G/A filed by Sangamo Therapeutics Inc. (Amendment)
$SGMO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/13/2024 | $7.00 | Hold → Buy | Truist |
12/10/2024 | $10.00 | Buy | H.C. Wainwright |
11/3/2023 | $6.00 → $2.00 | Outperform → Sector Perform | RBC Capital Mkts |
4/28/2023 | $5.00 → $1.50 | Neutral → Underperform | BofA Securities |
2/27/2023 | $16.00 | Neutral → Outperform | Wedbush |
1/6/2023 | $8.00 → $5.00 | Buy → Neutral | BofA Securities |
6/13/2022 | $5.00 | Neutral | Wedbush |